Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
278.6 USD | -3.34% | -0.28% | -8.41% |
11:54am | Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating | MT |
06-03 | Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study | MT |
Sales 2024 * | 19.8B 2.89B 3.94B | Sales 2025 * | 23.62B 3.44B 4.71B | Capitalization | 126B 18.3B 25.01B |
---|---|---|---|---|---|
Net income 2024 * | 4.68B 682M 932M | Net income 2025 * | 6.61B 964M 1.32B | EV / Sales 2024 * | 5.03 x |
Net cash position 2024 * | 25.92B 3.78B 5.16B | Net cash position 2025 * | 32.36B 4.72B 6.45B | EV / Sales 2025 * | 3.94 x |
P/E ratio 2024 * |
28.7
x | P/E ratio 2025 * |
20.6
x | Employees | 2,286 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Genmab A/S
1 day | +0.31% | ||
1 week | -0.28% | ||
Current month | +4.89% | ||
1 month | -2.51% | ||
3 months | +1.96% | ||
6 months | -10.55% | ||
Current year | -8.41% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-04 | 278.6 | -3.34% | 136 |
24-06-03 | 288.2 | +4.56% | 403 |
24-05-31 | 275.7 | -3.03% | 443 |
24-05-30 | 284.3 | +3.58% | 423 |
24-05-29 | 274.5 | -5.34% | 254 |
Delayed Quote OTC Markets, June 04, 2024 at 10:07 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.62% | 121B | |
+13.65% | 107B | |
-3.72% | 24.82B | |
+1.72% | 22.48B | |
-42.28% | 16.33B | |
-16.05% | 15.31B | |
+4.50% | 14.08B | |
+25.93% | 11.74B | |
+77.32% | 9.02B |
- Stock Market
- Equities
- GMAB Stock
- GNMSF Stock